Blueprint Medicines Completes Acquisition of Lengo Therapeutics…Expands Blueprint Medicines’ lung cancer pipeline with LNG-451, a highly selective brain-penetrant precision therapy targeting EGFR exon 20 insertion mutations. Investigational New Drug application for LNG-451 submitted to U.S. FDA by Lengo Therapeutics in December.